ITGB6: A Protein Involved in Cell-cell Adhesion and TGF-β Regulation

Target Name: ITGB6

NCBI ID: G3694

ITGB6

ITGB6: A Protein Involved in Cell-cell Adhesion and TGF-β Regulation

ITGB6 (integrin subunit beta 6) is a protein that is expressed in various tissues throughout the body, including the placenta, bone marrow, and peripheral blood cells. It is a member of the integrin family, which is a group of transmembrane proteins that play a critical role in cell-cell and cell-extracellular matrix interactions. ITGB6 is one of the six subunits of the integrin alpha chain, which consists of four subunits that form a monocistral protein.

The integrin system is involved in many physiological processes in the body, including cell adhesion, migration, and invasion. ITGB6 is specifically involved in cell-cell adhesion, which is critical for the development and maintenance of tissues and organs. ITGB6 helps to promote the stickiness of cells to each other by interacting with the adhesion molecule cadherin.

Despite the importance of ITGB6 in cell-cell adhesion, several studies have suggested that it may also have other functions. For example, ITGB6 has been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and ITGB6 has been shown to regulate the activity of the TGF-β transcription factor.

In addition to its role in cell-cell adhesion and TGF-β regulation, ITGB6 has also been suggested as a potential drug target or biomarker. Several studies have shown that ITGB6 can be targeted by small molecules, including inhibitors of the TGF-β pathway . These inhibitors have been shown to be effective in treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Targeting ITGB6

Several studies have shown that ITGB6 can be effectively targeted by small molecules. One of the most effective inhibitors of ITGB6 is a small molecule called U21247, which is a potent inhibitor of the TGF-β pathway. U21247 has been shown to inhibit the activity of ITGB6 and its downstream targets, including the transcription factor SMAD.

Another inhibitor of ITGB6 is a small molecule called TK-124, which is a potent inhibitor of the TGF-β pathway. TK-124 has been shown to inhibit the activity of ITGB6 and its downstream targets, including the transcription factor SMAD.

In addition to U21247 and TK-124, several other small molecules have also been shown to be effective inhibitors of ITGB6. These molecules include inhibitors of the F-actin domain of ITGB6, as well as inhibitors of the N-terminal domain of ITGB6.

Measuring ITGB6 activity

It is important to note that measuring ITGB6 activity can be a complex and challenging task. There are several methods that can be used to measure ITGB6 activity, including immunofluorescence, Western blotting, and biochemical assays.

Immunofluorescence is a common method for measuring ITGB6 activity. This technique involves the use of antibodies that recognize ITGB6 and can be used to detect the protein in a variety of cellular and tissue samples. Immunofluorescence can be used to measure the distribution of ITGB6 in different tissues and cellular samples, as well as to monitor changes in ITGB6 expression in response to different stimuli.

Western blotting is another method that can be used to measure ITGB6 activity. This technique involves the use of antibodies that recognize ITGB6 and can be used to detect the protein in a variety of cellular and extracellular matrix samples. Western blotting can be used to measure the concentration of ITGB6 in different samples, as well as to monitor changes in ITGB6 concentration in response to different stimuli.

Biochemical assays are also

Protein Name: Integrin Subunit Beta 6

Functions: Integrin alpha-V:beta-6 (ITGAV:ITGB6) is a receptor for fibronectin and cytotactin (PubMed:17545607, PubMed:17158881). It recognizes the sequence R-G-D in its ligands (PubMed:17545607, PubMed:17158881). Internalization of integrin alpha-V/beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion (PubMed:17545607, PubMed:17158881). ITGAV:ITGB6 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:17158881). Integrin alpha-V:beta-6 (ITGAV:ITGB6) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation (PubMed:15184403, PubMed:22278742, PubMed:28117447)

The "ITGB6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITGB6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets